First Cardiology Division, University of Athens, Hippokration General Hospital, Athens, Greece.
Department of Cardiology, Hippokration General Hospital, Athens, Greece.
J Cardiovasc Electrophysiol. 2019 Mar;30(3):299-307. doi: 10.1111/jce.13804. Epub 2018 Dec 26.
Cardiac perforation of the right ventricle associated with pacemaker or implantable cardioverter defibrillator (ICD) leads' implantation is uncommon, albeit potentially life-threatening, complication. The aim of this study is to further identify the optimal therapeutic strategy, especially when lead dislocation has occurred outside the pericardial sac.
The study population included 10 consecutive patients (six female, mean age: 66.5 years old) diagnosed with early ventricular lead perforation following a pacemaker or ICD implantation, with significant protrusion inside the pericardial sac (n = 2) or migration of the lead at the pleural space ( n = 3), the diaphragm ( n = 1), or the abdominal cavity ( n = 4), during the period 2013-2017. All patients were symptomatic; however, individuals presenting with hemodynamic instability were excluded. The outcome of the percutaneous therapeutic approach was retrospectively assessed. All patients underwent a successful removal of the perforating lead percutaneously at the electrophysiology lab, by direct traction, and repositioning in another location of the right ventricle. The operation was performed by a multidisciplinary team, under continuous hemodynamic and transesophageal echocardiographic monitoring and cardiac surgical backup. The periprocedural period was uneventful. Subjects were followed up for at least 1 year. Interestingly, all patients developed a type of postcardiac injury syndrome, successfully treated with a 3-month regimen of ibuprofen and colchicine.
Percutaneous traction and repositioning of the perforating ventricular lead are effective, safe, and less invasive compared with the thoracotomy method in hemodynamically stable patients when dislocation has occurred outside the pericardial sac provided that there is no visceral organs injury.
右心室的心脏穿孔与心脏起搏器或植入式心律转复除颤器(ICD)导联的植入相关,是一种罕见但潜在危及生命的并发症。本研究旨在进一步确定最佳治疗策略,尤其是当导联脱位发生在心包囊外时。
研究人群包括 2013 年至 2017 年间连续 10 例诊断为心脏起搏器或 ICD 植入后早期心室导联穿孔的患者,这些患者在心包囊内有明显突出(n=2)或导联迁移到胸膜腔(n=3)、膈肌(n=1)或腹腔(n=4)。所有患者均有症状;但排除了有血流动力学不稳定的患者。回顾性评估了经皮治疗方法的结果。所有患者均在电生理实验室通过直接牵引和将穿孔导联重新定位到右心室的另一个位置成功经皮取出穿孔导联。该手术由多学科团队进行,在持续的血流动力学和经食管超声心动图监测和心脏外科支持下进行。围手术期无不良事件发生。患者至少随访 1 年。有趣的是,所有患者均发生了一种心脏损伤后综合征,通过布洛芬和秋水仙碱 3 个月的治疗方案成功治愈。
在血流动力学稳定的患者中,当脱位发生在心包囊外且无内脏器官损伤时,与开胸手术相比,经皮牵引和重新定位穿孔的心室导联更有效、安全且微创。